BVS News and Press, Bioventus Inc. From 04/16/21

Point Roberts, WA and Delta, BC - April 16, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and leading retail investor and trader resource, announces its weekly roundup of stocks to watch in Biotech, Tech, Mining and Real Estate. Today's stocks have been adde...

DURHAM, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that first quarter of fiscal year 2021 financial results will be released after th...

Insider buying decreased significantly last week. Notable Insider Buys: HighPeak Energy, Inc., William Penn Bancorporation, Bioventus Inc., Athenex, Inc., Sensei Biotherapeutics, Inc. Notable Insider Sells: Facebook, Inc., Ulta Beauty, Inc., Guardant Health, Inc., Applied Material...

Bioventus (BVS) acquires Bioness, a global leader in neuromodulation and rehabilitation medical devices through its innovative peripheral nerve stimulation therapy and premium rehabilitation solutions.The transaction value is for $45M in up-front consideration, with up to $65M of conting...

DURHAM, N.C., March 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has acquired Bioness, Inc . (“Bioness”), a global leader in neuromodulation and ...

Bioventus (BVS): Q4 GAAP EPS of $0.10 beats by $0.07.Revenue of $98.59M (+1.1% Y/Y) beats by $0.51M.Press Release For further details see: Bioventus EPS beats by $0.07, beats on revenue

DURHAM, N.C., March 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the fourth quarter and year ended December 31, 2020. This press r...

Bioventus (BVS) reported that the first patients have been enrolled and dosed in its Phase 1 open-label, dose-escalation study evaluating the safety and efficacy of MOTYS ((PTP-001)) to treat osteoarthritis ((OA)) of the knee.Current treatments for knee OA are limited to corticosteroids ...

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported that the first patients have been enrolled and dosed in its Phase 1 open-label, dose-escalatio...